Your Health, We Care
On May 6, 2020, the U.S. Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for the treatment of metastatic non-small cell lung cancer (mNSCLC) with MET exon 14 skipping mutation.
On February 11, 2020, Novartis announced that the U.S. Food and Drug Administrat···【more】
Release date：2026-01-09Recommended：27
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administrat···【more】
Release date：2026-01-09Recommended：26
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells···【more】
Release date：2024-08-07Recommended：161
Capmatinib is highly selective for c-Met targets, can effectively inhibit the pr···【more】
Release date：2024-08-07Recommended：198
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or t···【more】
Release date：2024-08-06Recommended：162
